DailyIQ
|
Sector:HealthcareAll sectors
Last updated 5 minutes ago

BDX·Becton, Dickinson and Company

$.
+. (+.%)
After Hours
High
$152.90
Open
$150.52
Market Cap
42.03B
52W High
$187.35
Low
$150.15
P. Close
$151.97
P/E
36.93
52W Low
$127.59
Fwd P/E
11.34
DailyIQ Est.
$179.74
Technical Score (1D)
50
NEUTRAL
News Sentiment
56
BULLISH
The most immediate change is Becton, Dickinson’s upcoming Q3 fiscal‑2026 earnings release on August 6, which will be presented via an audio webcast. The company will detail revenue growth, margin trends and capital‑allocation plans, so the release will confirm whether its historical earnings‑beat streak continues and whether guidance aligns with the 7‑8 % revenue growth forecast. Investors should watch the guidance for any updates on the Vizient contract for the CentroVena One insertion system, which could lift revenue if volume targets are met. The contract, awarded 234.8 hours ago, expands BDX’s distribution network and may provide incremental sales, but execution risk remains a concern. The recent index reshuffle, adding BDX to the Russell Midcap and Midcap Value Benchmarks, could increase visibility and trading volume, yet the stock remains trading at a discount to DCF estimates. Analysts note that BDX’s high‑margin product lines and 2.78 % dividend support a potential upside, but Evercore’s price‑target cut to $180 signals modest valuation caution. The broader IV equipment market is projected to grow 6.1 % CAGR to 2031, offering a favorable tailwind for BDX’s infusion product portfolio. Over the next 1–10 trading days, traders should monitor the earnings webcast for guidance on revenue, margin and the status of the Vizient contract, as well as any updates on GLP‑1 related product revenue. Additionally, watch for post‑earnings commentary on the company’s capital‑allocation plans and potential changes in its valuation narrative.
Earnings Summary
Becton, Dickinson and Company (BDX) is a global medical technology firm that designs and manufactures a broad portfolio of medical supplies, devices, and diagnostic solutions, operating across Medical, Connected Care, BioPharma Systems, and Interventional and Life Sciences segments within the healthcare sector. The company’s focus on vascular access, medication management, and laboratory equipment places it firmly in the medical instruments and supplies industry, where innovation and regulatory compliance drive performance. In the most recent two quarters, BDX reported revenue of $5.252 billion in Q1 2026 and $4.714 billion in Q2 2026, a decline from the $5.890 billion recorded in Q3 2025 and the $5.152 billion estimate for Q4 2025, indicating a downward trend in top‑line growth. EPS, however, has shown mixed results: the company beat estimates in Q4 2024 ($3.43 vs. $2.989), Q1 2025 ($3.35 vs. $3.281), Q2 2025 ($3.68 vs. $3.402), and Q3 2025 ($3.96 vs. $3.915), but missed in Q1 2026 ($2.91 vs. $3.312) while beating in Q2 2026 ($2.90 vs. $2.775). This pattern reflects a consistent ability to exceed earnings expectations in most quarters, though revenue momentum has slowed. Historically, BDX has maintained a steady YoY revenue growth trajectory, with EPS rising from $3.43 in Q4 2024 to $3.96 in Q3 2025 before a slight dip in 2026. The company has repeatedly outperformed analyst estimates, especially in earnings, while revenue growth has occasionally decelerated, suggesting that profitability gains are not always matched by top‑line expansion. Recent news highlights BDX’s potential upside from a new Vizient contract for the CentroVena One insertion system, its positioning as a beneficiary of the expanding GLP‑1 drug market, and its shift into the Russell Midcap index, which could alter passive flow dynamics. These developments underscore the importance of product pipeline execution and market demand for GLP‑1 related devices. Investors should watch for the Q3 2026 earnings release, paying particular attention to guidance on GLP‑1 product sales, execution progress of the Vizient contract, and any updates on passive fund flows following the index change, as these factors will likely shape the company’s near‑term valuation and revenue outlook.

EPS

EstBeatMiss
$2.60$2.98$3.37$3.75$4.14Q1'25Q2'25Q3'25Q1'26Q2'26Q4'25
QtrEstActual+/−
Q4'25$2.81 - -
Q2'26$2.77$2.90+4.5%
Q1'26$3.31$2.91-12.1%
Q3'25$3.91$3.96+1.1%
Q2'25$3.40$3.68+8.2%
Q1'25$3.28$3.35+2.1%

Revenue

EstBeatMiss
$4.5B$4.9B$5.3B$5.7B$6.1BQ1'25Q2'25Q3'25Q1'26Q2'26Q4'25
QtrEstActual+/−
Q4'25$5.2B - -
Q2'26$4.7B$4.7B-0.0%
Q1'26$5.5B$5.3B-5.0%
Q3'25 - $5.9B -
Q2'25 - $5.5B -
Q1'25 - $5.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BDX Stock Snapshot

BDX is currently trading at $151.94, giving Becton, Dickinson and Company a market cap of 42.03B and a P/E ratio of 36.9. Today's range spans $150.15–$152.90, with shares opening at $150.52 and moving down $0.03 (0.0%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 56/100.

Over the past year BDX has traded between $127.59 and $187.35 - the current price is +19.1% off the 52-week low and -18.9% from the high. 23 analysts cover the stock with a Hold consensus and a mean 12-month target of $176.92 (range $150.00–$225.00), implying upside of +16.4%.

The setup for Becton, Dickinson and Company (BDX) is neither bullish nor bearish - it's patient. Score: 50/100 (HOLD). Sentiment: neutral (56/100). Price: $151.94 (in the lower half of its 52-week range in $127.59–$187.35). The current P/E ratio stands at 36.9. A large-cap with 42.03B in Healthcare market cap in a neutral technical phase is exactly where position-sizing decisions get made before the next trend emerges.

The 52-week range of $127.59–$187.35 for BDX provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $151.94 (in the lower half of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 50/100 and neutral news backdrop (56/100) don't break the tie yet, but they narrow the probability distribution toward the upside.